

Resource Summary Report

Generated by [dkNET](#) on Aug 7, 2026

CONFIRM anti-CD8 (SP57) Rabbit Monoclonal Primary Antibody

RRID:AB_2335985

Type: Antibody

Proper Citation

Roche Cat# 05937248001, RRID:AB_2335985

Antibody Information

URL: http://antibodyregistry.org/AB_2335985

Proper Citation: Roche Cat# 05937248001, RRID:AB_2335985

Target Antigen: CD8

Host Organism: rabbit

Clonality: monoclonal

Antibody Name: CONFIRM anti-CD8 (SP57) Rabbit Monoclonal Primary Antibody

Description: This monoclonal targets CD8

Clone ID: SP57

Antibody ID: AB_2335985

Vendor: Roche

Catalog Number: 05937248001

Alternative Catalog Numbers: 790-4460

Record Creation Time: 20250820T043454+0000

Record Last Update: 20250820T192151+0000

Ratings and Alerts

- Independent validation by the NYU Lagone was performed for: IHC. This antibody was found to have the following characteristics: Functional in human:TRUE, NonFunctional in human:FALSE, Functional in animal:FALSE, NonFunctional in animal:FALSE - NYU Langone's Center for Biospecimen Research and Development <https://med.nyu.edu/research/scientific-cores-shared-resources/center-biospecimen-research-development>

No alerts have been found for CONFIRM anti-CD8 (SP57) Rabbit Monoclonal Primary Antibody.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 30 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Ma X, et al. (2026) The Small Chemical Compound Repsox Potentiates Oct4-Driven Astrocyte-to-Neural Stem Cell Reprogramming via Notch1/Hes1/Smurf2 Pathway. Cellular and molecular neurobiology, 46(1).

Ren W, et al. (2025) Whole-genome sequencing reveals three follicular lymphoma subtypes with distinct cell of origin and patient outcomes. Cell reports. Medicine, 6(8), 102278.

Lee YJ, et al. (2025) Tumor-specific but immunosuppressive CD39+CD8+ T cells exhibit double-faceted roles in clear cell renal cell carcinoma. Cell reports. Medicine, 102360.

Sacco JJ, et al. (2025) Evolution of the tumor immune landscape during treatment with tebentafusp, a T cell receptor-CD3 bispecific. Cell reports. Medicine, 6(4), 102076.

Digomann D, et al. (2025) Soluble TIM-3 and galectin-9 predict survival in gastric and gastroesophageal junction cancer. iScience, 28(11), 113871.

Urai S, et al. (2025) Challenges in diagnosing paraneoplastic isolated adrenocorticotrophic hormone deficiency: Insights from cancer histology and human leukocyte antigen analysis. Journal of neuroendocrinology, e70074.

Shen F, et al. (2025) Human Kallikrein 2: A Novel Lineage-Specific Surface Target in Prostate Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 31(21), 4543.

Hockemeyer K, et al. (2024) The stress response regulator HSF1 modulates natural killer cell anti-tumour immunity. Nature cell biology, 26(10), 1734.

Donati B, et al. (2024) Spatial Distribution of Immune Cells Drives Resistance to Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer. Cancer immunology research, 12(1), 120.

Sun Y, et al. (2024) Integrated multi-omics profiling to dissect the spatiotemporal evolution of metastatic hepatocellular carcinoma. *Cancer cell*, 42(1), 135.

Urai S, et al. (2024) The early-stage clinical course of anti-pituitary-specific transcription factor-1 hypophysitis diagnosed post-immune checkpoint inhibitor treatment: A case with review of literature. *Journal of neuroendocrinology*, 36(6), e13395.

Li Y, et al. (2024) Multimodal immune phenotyping reveals microbial-T cell interactions that shape pancreatic cancer. *Cell reports. Medicine*, 5(2), 101397.

Kanzawa M, et al. (2024) Effects of the Cortisol Milieu on Tumor-Infiltrating Immune Cells in Corticotroph Tumors. *Endocrinology*, 165(4).

Tabata M, et al. (2023) Inter- and intra-tumor heterogeneity of genetic and immune profiles in inherited renal cell carcinoma. *Cell reports*, 42(7), 112736.

Basolo A, et al. (2023) Autopsy Study of Testicles in COVID-19: Upregulation of Immune-Related Genes and Downregulation of Testis-Specific Genes. *The Journal of clinical endocrinology and metabolism*, 108(4), 950.

Park JA, et al. (2023) Targeting tumor vasculature to improve antitumor activity of T cells armed ex vivo with T cell engaging bispecific antibody. *Journal for immunotherapy of cancer*, 11(3).

Urai S, et al. (2023) Paraneoplastic isolated adrenocorticotrophic hormone deficiency revealed after immune checkpoint inhibitors therapy: new insights into anti-corticotroph antibody. *Frontiers in immunology*, 14, 1284301.

van Hijfte L, et al. (2023) Alternative normalization and analysis pipeline to address systematic bias in NanoString GeoMx Digital Spatial Profiling data. *iScience*, 26(1), 105760.

Chiu D, et al. (2023) A Phase I Trial of VEGF-A Inhibition Combined with PD-L1 Blockade for Recurrent Glioblastoma. *Cancer research communications*, 3(1), 130.

Golesworthy B, et al. (2022) Intra-Tumoral CD8+ T-Cell Infiltration and PD-L1 Positivity in Homologous Recombination Deficient Pancreatic Ductal Adenocarcinoma. *Frontiers in oncology*, 12, 860767.